The approval of ZORYVE cream 0.15% for atopic dermatitis in Canada was supported by positive results from the vehicle-controlled pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials, in which ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially availableProvides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can ...

Roflumilast foam 0.3% is under review by Health Canada for the topical treatment of seborrheic dermatitis in adult and adolescent patients 9 years of age and older, supported by clinical results ...

Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. Zoryve ® cream contains ...

Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced today that Health Canada has approved PrZORYVE® (roflumilast cream 0.15%) ...

Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced today that Health Canada has approved PrZORYVE® (roflumilast cream 0 ...